

## CLAIMS

The invention claimed is:

1       1. A pharmaceutically useful compound for inhibiting immunostimulation by  
2       immunostimulatory sequence oligodeoxynucleotides (ISS-ODN), wherein the ISS-ODN contain  
3       a hexamer region consisting of at least one CpG nucleotide motif flanked by two 5' purines and two  
4       3' pyrimidines (ISS-ODN), comprising:

5               an oligonucleotide containing a hexamer region having the nucleotide sequence 5'-Purine-  
6       Purine-[Y]-[Z]-Pyrimidine-Pyrimidine-3' or 5'-Purine-Purine-[Y]-[Z]-Pyrimidine-poly(Pyrimidine)-3';

7               where Y is any naturally occurring or synthetic nucleotide except cytosine and Z is any  
8       naturally occurring or synthetic nucleotide; however, when Y is not guanosine or inosine, Z is  
9       guanosine or inosine.

10       2. The compound according to Claim 1 where Y is guanosine or inosine.

11       3. The compound according to Claim 1 where Y is inosine and Z is inosine or guanosine.

12       4. The compound according to Claim 1 where Y is guanosine and Z is guanosine or an  
13       unmethylated cytosine.

1       5. A pharmaceutically useful compound for inhibiting immunostimulation by  
2       immunostimulatory sequence oligodeoxynucleotides comprising an oligonucleotide containing a  
3       hexamer region having the nucleotide sequence AAGGTT.

1       6. A pharmaceutically useful compound for inhibiting immunostimulation by  
2       immunostimulatory sequence oligodeoxynucleotides comprising an oligonucleotide containing a  
3       hexamer region having a nucleotide sequence consisting of AAGCTT.

1       7. A pharmaceutically useful compound for inhibiting immunostimulation by  
2 immunostimulatory sequence oligodeoxynucleotides comprising an oligonucleotide containing a  
3 hexamer region having a nucleotide sequence consisting of AGGGCT

1       8. A pharmaceutically useful compound for inhibiting immunostimulation by  
2 immunostimulatory sequence oligodeoxynucleotides comprising an oligonucleotide containing a  
3 hexamer region having a nucleotide sequence consisting of GAGGTT.

1       9. A pharmaceutically useful compound for inhibiting immunostimulation by  
2 immunostimulatory sequence oligodeoxynucleotides comprising an oligonucleotide containing a  
3 hexamer region having a nucleotide sequence selected from the group of sequences consisting of  
4 AAGCTT, AGGCTC, GAGCTT, GGGCTT, AAGCTC, AGGCTC, GAGCTC, GGGCTC,  
5 AAGCCC, AGGCC, GAGCCC, GGGCCC, AGGCCT, GAGCCT, GGGGCT, TTGCAA,  
6 AATGTT, GGGGTT and AAGCCC.  
7  
8

1       10. The compound according to any of Claims 1 through 9 wherein the hexamer region is  
2 flanked by nucleotides in a sequence identical to the sequence of nucleotides which flank the  
3 hexamer region of any known ISS-ODN.

1       11. The compound according to any of Claims 1 through 9 wherein the oligonucleotide  
2 compound is conjugated to a peptide.

1       12. A kit for use in gene therapy or gene immunization consisting of any of the  
2 immunoinhibitory compounds of Claims 1 through 11 in a sterile vial and a recombinant expression  
3 vector in a sterile vial.

1       13. The kit according to Claim 12 wherein the immunoinhibitory compound and the recombinant  
2 expression vector are contained in the same sterile vial.

1       14. A method for inhibiting the immunostimulatory activity of ISS-ODN in contact with a  
2 population of vertebrate cells which includes lymphocytes or monocytes comprising contacting the  
3 population of vertebrate cells with an immunoinhibitory amount of an oligonucleotide containing  
4 a hexamer region having the nucleotide sequence 5'-Purine-Purine-[Y]-[Z]-Pyrimidine-Pyrimidine-3'  
5 or 5'-Purine-Purine-[Y]-[Z]-Pyrimidine-poly(Pyrimidine)-3', where Y is any naturally occurring or  
6 synthetic nucleotide except cytosine and Z is any naturally occurring or synthetic nucleotide;  
7 however, when Y is not guanosine or inosine, Z is guanosine or inosine; wherein a reduction in Th1  
8 type immune responses measured in the population of vertebrate cells indicates that the desired  
9 inhibition of ISS-ODN immunostimulatory activity has been achieved.

1       15. The method according to Claim 14 wherein the ISS-ODN are believed to be present in a  
2 recombinant expression vector.

1       16. The method according to Claim 15 wherein both the recombinant expression vector and the  
2 immunoinhibitory oligonucleotide are administered to a vertebrate host.

1       17. The method according to Claim 14 wherein the ISS-ODN are believed to be present in a  
2 microbe.

1       18. The method according to Claim 17 wherein the microbe has infected a vertebrate host and  
2 the microbe is contacted with the immunoinhibitory oligonucleotide by administering the  
3 oligonucleotide in an immunoinhibitory amount to the host.

1       19. The method according to Claim 18 wherein the vertebrate host has an autoimmune disease  
2 believed to be clinically related to infection of the host by the microbe.

3       20. A method for prolonging gene expression in a recombinant expression vector believed to  
4 contain at least one ISS-ODN comprising contacting the recombinant expression vector with an  
5 immunoinhibitory amount of an oligonucleotide containing a hexamer region having the nucleotide  
6 sequence 5'-Purine-Purine-[Y]-[Z]-Pyrimidine-Pyrimidine-3' or 5'-Purine-Purine-[Y]-[Z]-Pyrimidine-  
7 poly(Pyrimidine)-3', where Y is any naturally occurring or synthetic nucleotide except cytosine and  
8 Z is any naturally occurring or synthetic nucleotide; however, when Y is not guanosine or inosine,  
9 Z is guanosine or inosine; wherein gene expression for a longer period of time than is obtained from  
10 the same recombinant expression vector in the absence of contact with the immunoinhibitory  
11 oligonucleotide indicates that the desired prolongation of gene expression has been achieved.

1       21. The method according to Claim 20 wherein both the recombinant expression vector and the  
2 immunoinhibitory oligonucleotide are administered to a vertebrate host.

1       22. A method for reducing inflammation in a host in response to a microbial infection of the host  
2 comprising administering an immunoinhibitory amount of an oligonucleotide containing a hexamer  
3 region having the nucleotide sequence 5'-Purine-Purine-[Y]-[Z]-Pyrimidine-Pyrimidine-3' or 5'-  
4 Purine-Purine-[Y]-[Z]-Pyrimidine-poly(Pyrimidine)-3' to the host, where Y is any naturally occurring  
5 or synthetic nucleotide except cytosine and Z is any naturally occurring or synthetic nucleotide;  
6 however, when Y is not guanosine or inosine, Z is guanosine or inosine; wherein a reduction in Th1  
7 type immune responses against the infectious microbe measured in the host or a reduction in other  
8 clinical signs of inflammation in the host indicates that the desired reduction in host inflammation  
9 has been achieved.

1       23. A method for modulating the immunostimulatory activity of an ISS-ODN in contact with a  
2 population of vertebrate cells which includes lymphocytes or monocytes comprising contacting the  
3 population of vertebrate cells with an immunoinhibitory amount of an oligonucleotide containing  
4 a hexamer region having the nucleotide sequence 5'-Purine-Purine-[Y]-[Z]-Pyrimidine-Pyrimidine-3'  
5 or 5'-Purine-Purine-[Y]-[Z]-Pyrimidine-poly(Pyrimidine)-3', where Y is any naturally occurring or  
6 synthetic nucleotide except cytosine and Z is any naturally occurring or synthetic nucleotide;  
7 however, when Y is not guanosine or inosine, Z is guanosine or inosine; wherein a reduction in Th1  
8 type immune responses measured in the population of vertebrate cells indicates that the desired  
9 inhibition of ISS-ODN immunostimulatory activity has been achieved.

1       24. The method according to Claim 23 wherein both the ISS-ODN and the immunoinhibitory  
2 oligonucleotide are administered to a vertebrate host.

1       25. A method for boosting a Th2 type immune response to an antigen comprising contacting a  
2 population of antigen stimulated vertebrate cells including lymphocytes with an immunostimulatory  
3 amount of an oligonucleotide containing a hexamer region having the nucleotide sequence 5'-Purine-  
4 Purine-[Y]-[Z]-Pyrimidine-Pyrimidine-3' or 5'-Purine-Purine-[Y]-[Z]-Pyrimidine-poly(Pyrimidine)-3',  
5 where Y is any naturally occurring or synthetic nucleotide except cytosine and Z is any naturally  
6 occurring or synthetic nucleotide; however, when Y is not guanosine or inosine, Z is guanosine or  
7 inosine; wherein wherein a reduction in Th1 type immune responses or increase in antigen  
8 stimulated IgG1 production measured in the population of vertebrate cells indicates that the desired  
9 boost in Th2 type immune responses to the antigen has been achieved.

10 26. A method for identifying IIS-ON which inhibit the immunostimulatory activity of ISS-ODN  
11 comprising:

12 (a) contacting a population of antigen stimulated immune cells with an ISS-ODN to  
13 induce lymphocyte proliferation in; IFN $\beta$ , IFN- $\alpha$ , IFN- $\gamma$ , IL-12 and IL-18 cytokine secretion  
14 from; IgG1 antibody production by; or IgE suppression in, the population of antigen  
15 stimulated immune cells;

16 (b) measuring any change in the number of lymphocytes or levels of secreted cytokines  
17 and/or levels of IgE or IgG1 antibodies in the population of antigen stimulated cells after  
18 contact with the ISS-ODN;

19 (c) contacting the population of antigen stimulated cells with a candidate IIS-ON  
20 inhibitory oligonucleotide; and,

21 (d) measuring any change in the number of lymphocytes or levels of secreted IFN $\beta$ , IFN-  
22  $\alpha$ , IFN- $\gamma$ , IL-12 and IL-18 cytokines and/or levels of IgE or IgG1 antibodies in the  
23 population of antigen stimulated cells after contact with the oligonucleotide, wherein a  
24 decline in any of the measured values for lymphocyte proliferation, cytokine secretion or  
25 IgG1 antibody production, as well as an increase in IgE antibody production, as compared  
26 to the measurements taken in step (b) indicates that the oligonucleotide inhibits the  
27 immunostimulatory activity of the ISS-ODN of step (a).

28 27. The method according to Claim 26 wherein the candidate inhibitory oligonucleotide contains  
29 a hexamer region having the nucleotide sequence 5'-Purine-Purine-[Y]-[Z]-Pyrimidine-Pyrimidine-3'  
30 or 5'-Purine-Purine-[Y]-[Z]-Pyrimidine-poly(Pyrimidine)-3', where Y is any naturally occurring or  
31 synthetic nucleotide except cytosine and Z is any naturally occurring or synthetic nucleotide;  
32 however, when Y is not guanosine, adenine or inosine, Z is guanosine or inosine.

1       28. A pharmaceutically useful compound comprising an oligonucleotide identified according to  
2       the method of Claim 26 as one which inhibits the immunostimulatory activity of ISS-ODN.

3       29. A method for detecting ISS-ODN immunostimulatory activity in a host comprising:

4             (a) obtaining a sample of immune cells from the host, which cells are believed to been  
5       exposed to an antigen or autoantigen;

6             (b) measuring the levels of lymphocyte proliferation in; IFN $\beta$ , IFN- $\alpha$ , IFN- $\gamma$ , IL-12 and  
7       IL-18 cytokine secretion from; IgG1 antibody production by; or IgE suppression in, the  
8       sample of host immune cells;

9             (c) contacting the sample of host immune cells with an immunoinhibitory oligonucleo-  
10       tide (IIS-ON); and,

11             (d) measuring any change in the number of lymphocytes or levels of secreted IFN $\beta$ , IFN-  
12        $\alpha$ , IFN- $\gamma$ , IL-12 and IL-18 cytokines and/or levels of IgE, IgG2 or IgG1 antibodies in the  
13       sample of host immune cells after contact with the IIS-ON, wherein a decline in any of the  
14       measured values for lymphocyte proliferation, cytokine secretion or IgG2 antibody  
15       production, as well as an increase in IgG1 or IgE antibody production, as compared to the  
16       measurements taken in step (b), indicates that an ISS-ODN subject to inhibition by the IIS-  
17       ON is present in the sample of host immune cells.